Marker Therapeutics, Inc.

A major leap forward in cell therapy

Pancreatic Cancer Interim Results

The Company

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs

Marker Therapeutics today announced the appointment of Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs, effective August 15.

Read more

Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results

Marker Therapeutics today provided a corporate update and reported financial results for the second quarter ended June 30, 2019.

Read more